Alnylam price target raised to $280 from $248 at JPMorgan

JPMorgan analyst Jessica Fye raised the firm’s price target on Alnylam to $280 from $248 and keeps a Neutral rating on the shares. Heading into the European Society of Cardiology meeting this Friday, the firm updated the company’s model to reflect higher projections for TTR silencers on the back of recent key opinion leader feedback. The topline HELIOS-B results point to a strong profile for Amvuttra in this setting, the analyst tells investors in a research note. JPMorgan raised its TTR estimates and now project 2035 sales for Alnylam’s TTR silencer franchise of $6.4B.